Roche UK's spokesperson confided that the UK company feared it was like a 'broken record' unable to break out of arguments on price and value in which all sides have become entrenched.

Roche has said it plans to UK price its latest multiple sclerosis drug Ocrevus in line with its close rival from Novartis - aiming to undercut some established rivals. Approved in Europe earlier ...

Roche has forged a multiyear partnership with Oxford BioTherapeutics to find new targets for antibody-based cancer treatments ...

Roche Diagnostics is collaborating with the University of Liverpool to launch the Eye Cancer Artificial Intelligence Digital Bioresource (EYE-CAN-AID), a multi-modal image database that aims to boost ...

Roche’s up to $1 billion investment will provide access to Oxford BioTherapeutics’ antibody-drug conjugate platform for ...

Shareholders approved all proposals of the Board of Directors Severin Schwan was re-elected as Chairman of the Board of ...

An international survey on the uptake, trust, and future of real-time payments (RTP) from global analytics software leader ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, as the Swiss drugmaker seeks to boost its prospects in the booming ...

FRANKFURT (Reuters) -Swiss drugmaker Roche has abandoned global targets for a more diverse workforce to avoid penalties from ...